Use of a monoclonal antibody for quantitation of rabies vaccine glycoprotein by enzyme immunoassay.
The use of a monoclonal antibody specific for the envelope glycoprotein of rabies virus has been used in a direct enzyme immunoassay to quantify the glycoprotein content of rabies vaccines produced in two kinds of cell culture. The results of this direct enzyme immunoassay are well correlated with the in vivo NIH potency test. This test may be a useful tool to rapidly and accurately control the antigenic value of a vaccine. It could also be used for the "in process' control of vaccine production before deciding whether a vaccine batch may reasonably be subjected to the NIH potency test.
D000818:Animals; D000911:Antibodies, Monoclonal; D000956:Antigens, Viral / Q000032:analysis; D002478:Cells, Cultured; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D007124:Immunoenzyme Techniques; D051379:Mice; D011819:Rabies Vaccines / Q000032:analysis*; D011820:Rabies virus / Q000276:immunology
D000911:Antibodies, Monoclonal; D000956:Antigens, Viral; D006023:Glycoproteins; D011819:Rabies Vaccines